STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (November 2020)
34 slides from STRATA Skin Sciences's investor presentation, Nov 12, 2020
Slide 1: Driving Value to Dermatology Partners, Matching Patients with Clinics
Investor Presentation November 2020 Driving Value to Dermatology Partners Matching Patients with Clinics NASDAQ: SSKN
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that are deemed
Slide 3: STRATA Investment Highlights
STRATA Investment Highlights A Win-Win-Win CompanyFor patients – safest, most effective treatment, no side effectsFor clinics – stable increased revenue baseFor payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis
Slide 4: How XTRAC Works - Psoriasis
How XTRAC Works - Psoriasis 4 After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 150+ peer reviewed published clinical studies PASI
Slide 5: How XTRAC Works - Vitiligo
How XTRAC Works - Vitiligo Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-altering
Slide 6: XTRAC a True Partnership: A Complete Business Solution
XTRAC a True Partnership: A Complete Business Solution Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Support DTC Marketing 6
Slide 7: Domestic XTRAC Revenue Funnel
Domestic XTRAC Revenue Funnel 7 REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY VERIFY APPOINTMENTPrescription of treatment VERIFY XTRACTREATMENT Patient leads
Slide 8: XTRAC Helps Patients Live Clear, Live Free
XTRAC Helps Patients Live Clear, Live Free… https://youtu.be/GdMBliZYy70 8
Slide 9: 50,000 People See XTRAC Ads Daily
50,000 People See XTRAC Ads Daily 9
Slide 10: New Patient Growth in 2019; 86% Covered by Insurance
196% of Psoriasis and 76% of Vitiligo patients had XTRAC as a covered insurance benefit 2New Patients captured in STRATA reimbursement system 21% 21% New Patient Growth in 2019; 86% Covered by Insurance1 10
Slide 11: STRATA's Domestic Recurring Revenue Model
STRATA’s Domestic Recurring Revenue Model 11 + 74 Devices 23% Growth 2.3% Growth 13% Growth 1Reflects only partners that purchase treatment codes on an as needed basis. Other partners purchase codes on a fixed monthly billing 2Revenue is domestic recurring revenue, net of discounts and co-pay suppor
Slide 12: Growth of XTRAC Share in Groups
Growth of XTRAC Share in Groups *Combination of new XTRAC placements and Clinic acquisitions Domestic Install Base Growth Drivers 12 1,673 clinics owned by 49 roll-up groups221 (13%) of which are XTRAC partnersSTRATA signed strategic expansion agreements with major groups Expansion into group clinic
Slide 13: Domestic Market: Installed Base – sales and service engine
Domestic Market: Installed Base – sales and service engine 13 Territories color coded Overview813 Partner XTRAC Clinics160+ Sold XTRAC5 Regions26 Sales Territories15 Field Service TechsIn-House Call Center to Qualify LeadsOnly One Competitor in U.S.
Slide 14: Partner Academic Institutions
Partner Academic Institutions 14
Slide 15: International Market: Installed Base
International Market: Installed Base Strategic Growth TargetsMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.1,300 OUS devices sold and in servicePlacement recurring revenue model agreement e
Slide 16: Customer Engagement Under COVID-19
Customer Engagement Under COVID-19 Patient Outreach Program Q2 no DTC spend – Restarted August – expanding throughout Q3 and Q4Leverage in-house call centerReached out to hundreds of clinics and thousands of patientsInsurance requests 51% until mid-May/20, and 72% through end of June/20 now 90% in O
Slide 17: Q3 2020 highlights
Q3 2020 highlights Gross domestic billings $4.7M, a 155% increase from Q2 2020Recurring gross margins 64.3% of revenue up 13.1% from Q2 2020Global recurring installed base 837 XTRAC devicesDomestic recurring installed base 813 – up 24 from Q2 2020International recurring installed base 24 – up 7 from
Slide 18: Financial Metrics
Financial Metrics 18 Note: all quarterly numbers are unaudited *Total recurring revenue over total installed base
Slide 19: Cap Table - Shares and Share Equivalents
(As of November 10, 2020) * Does not include 150K warrants that have a weighted average exercise price of $5.60 as of September 30, 2020 of which 130K expire by December 2020* Does not include 4.9M options that have a weighted average exercise price of $1.90 as of September 30, 2020 19 Cap Table - S
Slide 20: STRATA Investment Highlights
STRATA Investment Highlights A Win-Win-Win CompanyFor patients – safest, most effective treatment, no side effectsFor clinics – stable increased revenue baseFor payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis
Slide 21: Driving Value to Dermatology Partners Matching Patients with Clinics
Investor Presentation November 2020 Driving Value to Dermatology Partners Matching Patients with Clinics NASDAQ: SSKN
Slide 22: Appendix
Appendix 22
Slide 23: Additional Creative
Additional Creative 23 https://youtu.be/LbmTKkN0Aq4
Slide 24: XTRAC Excimer laser is FDA cleared for Psoriasis, Vitiligo, Atopic Dermatitis and Leukoderma
XTRAC® Excimer laser is FDA cleared for Psoriasis, Vitiligo, Atopic Dermatitis and Leukoderma. It uses a highly targeted beam of 308nm UVB to treat affected skin without damaging surrounding healthy tissue. Treatment has minimal side effects, avoids messy topicals and high cost of biologics. #1 Pres
Slide 25: Continuous Technology Investment and Business Growth
Continuous Technology Investment and Business Growth 25 510 (K) FDA Approval AL-7000 Ultra Velocity 400 Velocity 700 Velocity 7 Series S3 2000 2005 2008 2010 2014 2018 CPT Code Approval DTC Platform Creation 510 (K) FDA Approval (MMD)* Full Insurance Reimbursement 2012 *MMD tip is a diagnostic acces
Slide 26: Historical phototherapy utilization
26 Historical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B. 30% 30% Annual Growth in Excimer Laser U
Slide 27: Sample Studies from 150+ Clinical Studies
Multicenter Psoriasis Study1 Scalp Study3 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet
Slide 28: XTRAC a Preferred Treatment for 90% of Psoriasis Patients
Source: National Psoriasis Foundation XTRAC a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA) 28
Slide 29: Opportunity Map for XTRAC Indications
Opportunity Map for XTRAC Indications Prevalence Source Atopic Dermatitis 18 Million National Eczema Association Vitiligo 2-5 Million Vitiligo Support Psoriasis 7.5 Million NPF Topicals/Targeted Phototherapy Systemics/Biologics/UVB Booth Recommended Actual XTRAC Biologics 29
Slide 30: Phototherapy has Highest Patient Perceived Treatment Effectiveness
Source: Findings From the National Psoriasis Foundation Surveys, 2003-2011 (n=5604) Source: Real-world health outcomes study sponsored by Eli Lilly (n=2200) Phototherapy has Highest Patient Perceived Treatment Effectiveness 30
Slide 31: Leads, Appointments, RDX Charts
Leads, Appointments, RDX Charts 2015 2016 2017 2018 2019 Leads 36,473 21,296 7,269 22,213 47,911 Appointments 10,032 6,524 2,563 3,856 5,924 RDX Charts 26,237 23,481 18,747 18,107 21,989 31
Slide 32: Total Calls in Call Center
Total Calls in Call Center 300,000 253,278 250,000 208,054 200,000 140,202 150,000 125,449 100,000 67,129 ™ LJ ° 2015 2016 2017 2018 2019 Total Calls STRATA
Slide 33: XTRAC Adds (Delegated) Recurring Revenue Driver for its Partners
XTRAC Adds (Delegated) Recurring Revenue Driver for its Partners Treatment Patient Type Reimbursement Details Annual Revenue per Patient Can be delegated** XTRAC Mild / moderate / severe CPT Code 96920-96922 ($168-$251) average $186; 16 tx/course (2/yr) and Office Visit -$70 (2/Yr) $6,092 Photothe
Slide 34: How XTRAC Works for Offices: $250 Revenue in Less than Minutes
How XTRAC Works for Offices: $250 Revenue in Less than 7 Minutes Established CPT Codes 2019 National Medicare Average Rate 96920 - $167.2296921 - $183.4496922 - $249.03 34
STRATA Skin Sciences — Investor Presentation (November 2020) on 6ix